RUXCOVID phase 3 RCT ruxolitinib (5mg bid x 14d) + plus standard care in 432 hospitalized COVID-19 showed no benefit over placebo in day 29 primary outcomes (death, respiratory failure (invasive ventilation), or ICU care. https://t.co/eyAit2uOLi https://t.co/R9rA1A4dm5